The proteasome inhibitor bortezomib has been shown to sensitise cells to TRAIL in other types of cancer.29 We therefore aimed to investigate whether concentrations of bortezomib with only low single-agent toxicity synergise with TRAIL in HPV+ HNSCC cells. The gene discussed is TNFSF10; the disease is cancer.